News

Phase II trial approved for TLD-1433

Research Ethics Board approval has been obtained to move TLD-1433 to a Phase II trial for non-muscle invasive bladder cancer, using the…

Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

Three patients (patients four, five and six) were enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with patient 4 successfully achieving…

Excellent patient health update

Patients five and six remain cancer-free after one year and nine months, respectively, of their single treatment with TLD-1433! In other news,…

Patient 6: Cancer-free at six months

Following the success of Patient 5, Patient 6 has now also demonstrated no recurrence of bladder cancer at the 180 day clinical…

Patient 5: Cancer-free at six months

Patient 5 tolerated the single-dose treatment well, and has demonstrated no tumor recurrence or presence of disease at the 180 day clinical…

Phase Ib trial successfully completed

Based on the encouraging results of the first patients in the trial, the Medical and Scientific Advisory Board (“MSAB”) unanimously recommended the…

AGM videos online

Theralase has released three videos that were presented at its annual meeting. They cover the successful completion of the Phase Ib trial,…

More great news from the clinical trial

Very encouraging news from the clinic! Patient Five shows no clinical evidence or presence of NMIBC (non muscle invasive bladder cancer) at…

Sixth patient treated

A sixth patient — the third to receive the full therapeutic dose — has been treated. The primary, secondary, and exploratory endpoints…

Fifth patient treated for cancer

A fifth patient has been treated for non-muscle invasive bladder cancer with our drug TLD-1433. Consult the press release for more information.